Current opinion in lipidology最新文献_第6页

Dietary fat, telomere length and cognitive function: unravelling the complex relations. 膳食脂肪、端粒长度与认知功能:揭开复杂关系。

IF 4.4 3区医学

Current opinion in lipidology Pub Date : 2024-02-01 Epub Date: 2023-11-29 DOI: 10.1097/MOL.0000000000000900

Hamza Mostafa, Laia Gutierrez-Tordera, Javier Mateu-Fabregat, Christopher Papandreou, Mònica Bulló

{"title":"Dietary fat, telomere length and cognitive function: unravelling the complex relations.","authors":"Hamza Mostafa, Laia Gutierrez-Tordera, Javier Mateu-Fabregat, Christopher Papandreou, Mònica Bulló","doi":"10.1097/MOL.0000000000000900","DOIUrl":"10.1097/MOL.0000000000000900","url":null,"abstract":"Purpose of review: The review aims to explore the recent evidence on the associations between different dietary fat intake and cognitive function, and to understand the role of telomere length in this relationship.Recent findings: Clinical and preclinical studies included in this review suggest that dietary fat intake is associated with cognitive function and telomere length. High intake of saturated fats and trans fats, commonly found in ultra-processed foods, appears to have negative effects on cognitive function and telomere length, while other dietary fats, such as omega-3 polyunsaturated fatty acids and monounsaturated fatty acids are associated with improved cognitive performance and reduced telomere attrition. Controversial results related to omega-6 polyunsaturated fatty acids intake and its impact on cognitive function were found. Dietary fats may affect telomere length and cognition through oxidative stress, inflammation, and insulin resistance.Summary: The current review illustrated the relationship between dietary fat and cognitive function by focusing on the role of telomere length as a potential intermediator. More future studies are required, however, in order to develop targeted interventions aimed at preserving cognitive well-being throughout life.","PeriodicalId":11109,"journal":{"name":"Current opinion in lipidology","volume":" ","pages":"33-40"},"PeriodicalIF":4.4,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138451170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pregnancy, cardiovascular health, and microchimerism. 怀孕、心血管健康和微嵌合。

IF 4.4 3区医学

Current opinion in lipidology Pub Date : 2024-02-01 Epub Date: 2023-11-20 DOI: 10.1097/MOL.0000000000000914

Sara Hallum Søndergaard, Mads Kamper-Jørgensen

引用次数: 0

Circulating cell-free DNA and its association with cardiovascular disease: what we know and future perspectives. 循环无细胞DNA及其与心血管疾病的关系：我们所知道的和未来的展望。

IF 4.4 3区医学

Current opinion in lipidology Pub Date : 2024-02-01 Epub Date: 2023-10-06 DOI: 10.1097/MOL.0000000000000907

Steffen Ullitz Thorsen, Kristine Frøsig Moseholm, Frederik Banch Clausen

{"title":"Circulating cell-free DNA and its association with cardiovascular disease: what we know and future perspectives.","authors":"Steffen Ullitz Thorsen, Kristine Frøsig Moseholm, Frederik Banch Clausen","doi":"10.1097/MOL.0000000000000907","DOIUrl":"10.1097/MOL.0000000000000907","url":null,"abstract":"Purpose of review: The aim of this review is to explore a possible link between cell-free DNA (cfDNA) and cardiovascular disease (CVD), which may hold valuable potential for future diagnostics.Recent findings: cfDNA has become topic of high interest across several medical fields. cfDNA is used as a diagnostic biomarker in cancer, prenatal care, and transplantation. In addition, cfDNA may play an unrecognized role in biological processes that are involved in or underlying various disease states, for example, inflammation. Elevated levels of cfDNA are associated with various elements of CVD, cardio-metabolic risk factors, and autoimmune diseases. Mitochondrial cfDNA and neutrophil extracellular traps may play distinct roles. Total circulating cfDNA may reflect the unspecific accumulation of stressors and the organism's susceptibility and resilience to such stressors. As such, cfDNA, in a stressful situation, may provide predictive value for future development of CVD. We suggest exploring such possibility through a large-scale prospective cohort study of pregnant women.Summary: There is no doubt that cfDNA is a valuable biomarker. For CVD, its potential is indicated but less explored. New studies may identify cfDNA as a valuable circulating cardiovascular risk marker to help improve risk stratification.","PeriodicalId":11109,"journal":{"name":"Current opinion in lipidology","volume":" ","pages":"14-19"},"PeriodicalIF":4.4,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41116278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial introductions. 编辑介绍。

IF 4.4 3区医学

Current opinion in lipidology Pub Date : 2024-02-01 Epub Date: 2023-12-20 DOI: 10.1097/MOL.0000000000000912

引用次数: 0

Genetic variation in apolipoprotein A-V in hypertriglyceridemia. 高甘油三酯血症中载脂蛋白 A-V 的遗传变异。

IF 4.4 3区医学

Current opinion in lipidology Pub Date : 2023-12-21 DOI: 10.1097/mol.0000000000000916

Shehan D Perera, Robert A Hegele

引用次数: 0

Bempedoic acid: new evidence and recommendations on use. 双鱼藤酸：新证据和使用建议。

IF 4.4 3区医学

Current opinion in lipidology Pub Date : 2023-12-11 DOI: 10.1097/mol.0000000000000911

Kristina Paponja, Ivan Pećin, Željko Reiner, Maciej Banach

引用次数: 0

Angiopoietin-like 3 inhibition and the liver: less is more? 血管生成素样3抑制与肝脏：少即是多？

IF 4.4 3区医学

Current opinion in lipidology Pub Date : 2023-12-01 Epub Date: 2023-10-11 DOI: 10.1097/MOL.0000000000000898

Reindert F Oostveen, G Kees Hovingh, Erik S G Stroes

{"title":"Angiopoietin-like 3 inhibition and the liver: less is more?","authors":"Reindert F Oostveen, G Kees Hovingh, Erik S G Stroes","doi":"10.1097/MOL.0000000000000898","DOIUrl":"10.1097/MOL.0000000000000898","url":null,"abstract":"Purpose of review: The aim of this study was to discuss the potential mechanisms and implications of the opposing liver safety results from recent angiopoietin-like 3 (ANGPTL3) inhibition studies.Recent findings: The clinical development of vupanorsen, a N-acetylgalactosamine (GalNAc) antisense targeting hepatic ANGPTL3, was recently discontinued due to a significant signal of liver transaminase increase. Vupanorsen elicited a dose-dependent increase in hepatic fat fraction up to 75%, whereas the small interfering RNA (siRNA) ARO-ANG3, has reported preliminary evidence of a dose-dependent decrease in hepatic fat fraction up to 30%.Summary: ANGPTL3 inhibition is an attractive therapeutic target to reduce all apoB-containing lipoproteins. The discrepancy in liver signal results between the antisense and siRNA approach may be explained by the level of target inhibition. An alternative explanation may relate to off-target effects of vupanorsen, which have a molecule- and/or platform-specific origin. For intrahepatic strategies, highly potent ANGPTL3 inhibition will for now require special attention for liver safety.","PeriodicalId":11109,"journal":{"name":"Current opinion in lipidology","volume":" ","pages":"267-271"},"PeriodicalIF":4.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41194321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictors of cardiovascular risk in familial hypercholesterolemia. 家族性高胆固醇血症心血管风险的预测因素。

IF 4.4 3区医学

Current opinion in lipidology Pub Date : 2023-12-01 Epub Date: 2023-09-28 DOI: 10.1097/MOL.0000000000000903

Manuel Jesús Romero-Jiménez, María Elena Mansilla-Rodríguez, Eva Nadiejda Gutiérrez-Cortizo

{"title":"Predictors of cardiovascular risk in familial hypercholesterolemia.","authors":"Manuel Jesús Romero-Jiménez, María Elena Mansilla-Rodríguez, Eva Nadiejda Gutiérrez-Cortizo","doi":"10.1097/MOL.0000000000000903","DOIUrl":"10.1097/MOL.0000000000000903","url":null,"abstract":"Purpose of review: Familial hypercholesterolemia is associated with an increased risk of cardiovascular disease. The current international guidelines of the main scientific societies consider that, all people with Familial Hypercholesterolemia have a high or very high cardiovascular risk. However, the occurrence of atherosclerotic cardiovascular disease is very heterogeneous in this population. Stratifying risk within people with familial hypercholesterolemia is essential to identify individuals who require intensive cholesterol-lowering therapies.Recent findings: In the last year, several studies have been published focusing on the contribution of diabetes to Familial Hypercholesterolemia, the role of stroke, as a manifestation of atherosclerotic disease, and the external validation of the SAFEHEART risk equation in the English population diagnosed with Familial Hypercholesterolemia.Summary: It is necessary the development of a tool that allows us to identify, in a simple, reproducible, and universal way, patients who may have a high risk of suffering a cardiovascular event and who are susceptible to more intensive treatments to reduce cholesterol levels.","PeriodicalId":11109,"journal":{"name":"Current opinion in lipidology","volume":" ","pages":"272-277"},"PeriodicalIF":4.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41116206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sweet swell of burning fat: emerging role of high-density lipoprotein in energy homeostasis. 燃烧脂肪的甜味膨胀：高密度脂蛋白在能量稳态中的新作用。

IF 4.4 3区医学

Current opinion in lipidology Pub Date : 2023-12-01 Epub Date: 2023-10-05 DOI: 10.1097/MOL.0000000000000904

Anatol Kontush, Maximiliano Martin, Fernando Brites

引用次数: 0

Strategies of improving adherence to lipid-lowering therapy in patients with atherosclerotic cardiovascular disease. 改善动脉粥样硬化性心血管疾病患者降脂治疗依从性的策略。

IF 4.4 3区医学

Current opinion in lipidology Pub Date : 2023-12-01 Epub Date: 2023-08-18 DOI: 10.1097/MOL.0000000000000896

Dean G Karalis

{"title":"Strategies of improving adherence to lipid-lowering therapy in patients with atherosclerotic cardiovascular disease.","authors":"Dean G Karalis","doi":"10.1097/MOL.0000000000000896","DOIUrl":"10.1097/MOL.0000000000000896","url":null,"abstract":"Purpose of review: Lowering LDL-C has been shown to reduce ASCVD events, yet many ASCVD patients do not achieve their guideline-directed LDL-C goals leaving patients at increased risk of another ASCVD event. This review discusses implementation strategies to improve guideline-directed lipid management in patients with ASCVD focusing on the provider, patient, and system level.Recent findings: At a provider level, under-prescribing of statin intensity due most often to statin intolerance, clinical inertia, insufficient monitoring of LDL-C levels, and the difficulty and cost of prescribing other lipid-lowering therapies such as the PCSK9 inhibitors leads to suboptimal cholesterol management in ASCVD patients. Patients concerns about medication side effects and lack of understanding of their ASCVD risk are causes of poor adherence to their lipid-lowering therapy as are barriers at a system level.Summary: To improve cholesterol management in ASCVD patients will require an integrated approach targeting the provider, the patient and the system. There is a need for further education of clinicians on the importance of intensive LDL-C lowering in ASCVD patients and greater use of nonstatin LDL-C-lowering therapies for those patients on a maximally tolerated statin who have not achieved their guideline-directed LDL-C goal. This will require shared decision-making with a focus on patient education and patient-clinician communication so that the clinician's goals and aims align with that of the patient.","PeriodicalId":11109,"journal":{"name":"Current opinion in lipidology","volume":" ","pages":"252-258"},"PeriodicalIF":4.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10021314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1